BRPI0307976B8 - processo para a ligação seletiva de uma forma anormal agregativa de uma proteína, e, processo ou ensaio quanto à presença de uma forma agregativa anormal de uma proteína de uma amostra - Google Patents

processo para a ligação seletiva de uma forma anormal agregativa de uma proteína, e, processo ou ensaio quanto à presença de uma forma agregativa anormal de uma proteína de uma amostra

Info

Publication number
BRPI0307976B8
BRPI0307976B8 BRPI0307976A BRPI0307976A BRPI0307976B8 BR PI0307976 B8 BRPI0307976 B8 BR PI0307976B8 BR PI0307976 A BRPI0307976 A BR PI0307976A BR PI0307976 A BRPI0307976 A BR PI0307976A BR PI0307976 B8 BRPI0307976 B8 BR PI0307976B8
Authority
BR
Brazil
Prior art keywords
protein
abnormal
aggregative
assay
sample
Prior art date
Application number
BRPI0307976A
Other languages
English (en)
Inventor
Reza Lane Amin
J Stanley Christopher
Mark Wilson Stuart
Original Assignee
Microsens Biophage Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0307976(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204797A external-priority patent/GB0204797D0/en
Priority claimed from GB0216808A external-priority patent/GB0216808D0/en
Priority claimed from GB0229614A external-priority patent/GB0229614D0/en
Application filed by Microsens Biophage Ltd filed Critical Microsens Biophage Ltd
Publication of BRPI0307976A2 publication Critical patent/BRPI0307976A2/pt
Publication of BRPI0307976B1 publication Critical patent/BRPI0307976B1/pt
Publication of BRPI0307976B8 publication Critical patent/BRPI0307976B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

processo para a ligação seletiva de uma forma anormal agregativa de uma proteína, processo ou ensaio quanto à presença de uma forma agregativa anormal de uma proteína de uma amostra, e, agente de ligação. as formas agregativas infecciosas de proteínas, tais como prp, amilóide e tau, são ligadas seletivamente na presença da proteína de forma normal, empregando-se um agente de ligação poliônica, tal como sulfato de dextrano ou pentosano (aniônico), ou compostos de poliamina, tais como pdadmac (catiônico), sob condições de ligação seletiva, incluindo o uso de n-lauroil sarcosina em ph suavemente alcalino, e podem então ser ensaiadas.
BRPI0307976A 2002-02-28 2003-02-28 processo para a ligação seletiva de uma forma anormal agregativa de uma proteína, e, processo ou ensaio quanto à presença de uma forma agregativa anormal de uma proteína de uma amostra BRPI0307976B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0204797A GB0204797D0 (en) 2002-02-28 2002-02-28 Selective binding of pathological forms of prion proteins
GB0204797.5 2002-02-28
GB0216808A GB0216808D0 (en) 2002-07-18 2002-07-18 Selective binding of pathological forms of prion proteins
GB0216808.6 2002-07-18
GB0229614.3 2002-12-19
GB0229614A GB0229614D0 (en) 2002-12-19 2002-12-19 Selective binding of pathological forms of prion proteins
PCT/GB2003/000858 WO2003073106A2 (en) 2002-02-28 2003-02-28 Binding of pathological forms of prion proteins

Publications (3)

Publication Number Publication Date
BRPI0307976A2 BRPI0307976A2 (pt) 2016-06-21
BRPI0307976B1 BRPI0307976B1 (pt) 2017-12-19
BRPI0307976B8 true BRPI0307976B8 (pt) 2021-07-27

Family

ID=27767735

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0307976A BRPI0307976B8 (pt) 2002-02-28 2003-02-28 processo para a ligação seletiva de uma forma anormal agregativa de uma proteína, e, processo ou ensaio quanto à presença de uma forma agregativa anormal de uma proteína de uma amostra

Country Status (13)

Country Link
US (2) US7659076B2 (pt)
EP (1) EP1478931B2 (pt)
JP (1) JP4550425B2 (pt)
CN (1) CN100526884C (pt)
AU (1) AU2003214375B2 (pt)
BR (1) BRPI0307976B8 (pt)
CA (1) CA2477569C (pt)
CO (1) CO5611225A2 (pt)
ES (1) ES2564293T5 (pt)
MX (1) MXPA04008275A (pt)
NZ (1) NZ535276A (pt)
RU (1) RU2309410C2 (pt)
WO (1) WO2003073106A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
AU2002320045B2 (en) * 2001-05-31 2008-05-08 Adlyfe, Inc. Misfolded protein sensor method
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
ES2564293T5 (es) * 2002-02-28 2019-04-04 Microsens Biophage Ltd Enlazamiento de formas patológicas de proteínas priónicas
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
ES2398394T3 (es) 2003-08-13 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Reactivos peptídicos específicos de prión
DE10354207B8 (de) * 2003-11-20 2006-06-14 Priontype Gmbh & Co.Kg Verfahren zum Nachweis von pathologisch veränderten Prion-Proteinen (PrPSc) und Kit zur Durchführung des Verfahrens
FR2865280B1 (fr) * 2004-01-20 2007-01-12 Biomerieux Sa Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique
JP4934021B2 (ja) * 2004-04-05 2012-05-16 アイデックス ラボラトリーズ インコーポレイテッド 伝染性海綿状脳症試験の試薬及び方法
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US20090130774A1 (en) * 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
WO2006076497A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP2386861A3 (en) * 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-ß structure binding compounds
FR2888937B1 (fr) * 2005-07-21 2012-10-26 Biomerieux Sa Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
WO2007030804A1 (en) 2005-09-09 2007-03-15 Novartis Ag Prion-specific peptoid reagents
HUE025489T2 (en) * 2006-01-17 2016-04-28 Somalogic Inc Multiplexed analysis of test samples
DE102006010647A1 (de) * 2006-03-06 2007-09-13 Latza, Reinhard, Dr.med. Test zum Nachweis von pathologischen Prionen
US7601506B2 (en) 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
CA2721770A1 (en) * 2007-04-18 2008-10-30 Biochromix Ab Medical use of conjugated polyelectrolytes
JP4246777B1 (ja) * 2007-11-20 2009-04-02 森永乳業株式会社 異常型プリオン蛋白質結合剤および異常型プリオン蛋白質の検出方法
JP2011520108A (ja) * 2008-04-30 2011-07-14 ノバルティス アーゲー 病原性配座異性体についてのアッセイ
US9072370B2 (en) * 2008-06-19 2015-07-07 Colgate-Palmolive Company User health profiles derived from oral care implements
CN102725639A (zh) * 2009-11-04 2012-10-10 诺华有限公司 蛋白质聚集物与单体分离中作为结合试剂的带正电物质
JP2013032295A (ja) * 2009-12-04 2013-02-14 Kaneka Corp タウ蛋白の吸着材および吸着除去システム
EP2392342A1 (en) 2010-06-04 2011-12-07 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Compositions for use in the treatment or diagnosis of prion diseases
FR2973114A1 (fr) 2011-03-21 2012-09-28 Ets Francais Du Sang Nanobilles recouvertes de plasminogene comme support direct d'amplification cyclique de la proteine prion prpsc
ITMI20130112A1 (it) 2013-01-24 2014-07-25 Chemi Spa Metodo di qualificazione di preparazioni di pentosan polifosfato, sue materie prime e processi di produzione
WO2017044710A1 (en) * 2015-09-11 2017-03-16 Corning Incorporated Compositions and methods for nucleic acid purification from blood samples
GB201518675D0 (en) 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
JP6668459B2 (ja) 2016-04-13 2020-03-18 株式会社Ｌｓｉメディエンス 硫酸化多糖類を用いた免疫学的測定法
CN109517166B (zh) * 2018-10-25 2021-01-22 天津大学 疏水基团修饰的羧基端聚酰胺胺树状分子和制备方法及其抑制β淀粉样蛋白聚集的应用
EP4130741B1 (en) * 2020-03-31 2026-01-28 Fujirebio Inc. Method for immunoassay of amyloid beta in blood, and kit for same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US5429746A (en) † 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
EP1416280A3 (en) * 1995-09-14 2005-08-10 The Regents of the University of California Antibodies specific for native PrPsc
US6162931A (en) * 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
US5808011A (en) * 1996-07-01 1998-09-15 Biopure Corporation Method for chromatographic removal of prions
US6419916B1 (en) 1999-06-01 2002-07-16 The Regents Of The University Of California Assay for compounds which affect conformationally altered proteins
US6221614B1 (en) 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
US5977324A (en) 1998-02-20 1999-11-02 The Regents Of The University Of California Process for concentrating protein with disease-related conformation
GB2335490B (en) * 1998-03-20 2003-05-14 Ortho Clinical Diagnostics An assay surface that permits an analyte releasiing step
US6150172A (en) † 1999-01-08 2000-11-21 The United States Of America As Represented By The Secretary Of Agriculture Method and kit for extracting prion protein
IL146769A0 (en) * 1999-06-01 2002-07-25 Univ California Method of sterilizing
JP2003514773A (ja) 1999-09-28 2003-04-22 ウニヴェルジテート チューリッヒ 血清及び血漿中のプリオン結合活性を有する因子並びに伝染性海綿状脳障害を検出するための薬剤
BR0111975A (pt) * 2000-06-26 2003-07-01 Universitot Zuerich Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator
JP2002056658A (ja) * 2000-08-04 2002-02-22 Pioneer Electronic Corp メニュー選択装置
DE10107083C2 (de) * 2001-02-13 2003-02-20 Abdulgabar Salama Pentosan Polysulfat als Ligand zum Nachweis von Prionen
AR035956A1 (es) * 2001-04-17 2004-07-28 Femtolink Biotechnologies Llc Deteccion y cuantificacion de isoformas de prion en enfermedades neurodegenerativas mediante espectrometria de masas.
ES2564293T5 (es) * 2002-02-28 2019-04-04 Microsens Biophage Ltd Enlazamiento de formas patológicas de proteínas priónicas

Also Published As

Publication number Publication date
EP1478931B2 (en) 2018-11-07
MXPA04008275A (es) 2005-04-25
US8460885B2 (en) 2013-06-11
US20050221404A1 (en) 2005-10-06
BRPI0307976B1 (pt) 2017-12-19
WO2003073106A2 (en) 2003-09-04
US7659076B2 (en) 2010-02-09
US20100184054A1 (en) 2010-07-22
RU2004128924A (ru) 2005-06-10
WO2003073106A3 (en) 2004-01-08
JP2005519088A (ja) 2005-06-30
BRPI0307976A2 (pt) 2016-06-21
EP1478931A2 (en) 2004-11-24
AU2003214375A1 (en) 2003-09-09
CO5611225A2 (es) 2006-02-28
CN100526884C (zh) 2009-08-12
CA2477569A1 (en) 2003-09-04
CN1643381A (zh) 2005-07-20
AU2003214375B2 (en) 2008-05-08
RU2309410C2 (ru) 2007-10-27
NZ535276A (en) 2008-04-30
ES2564293T3 (es) 2016-03-21
ES2564293T5 (es) 2019-04-04
CA2477569C (en) 2013-09-24
EP1478931B1 (en) 2015-12-30
JP4550425B2 (ja) 2010-09-22

Similar Documents

Publication Publication Date Title
WO2003073106A3 (en) Binding of pathological forms of prion proteins
WO2005052542A3 (en) Method and composition useful for determining fk 506
EP1597350A4 (en) NUCLEIC ACID MOLECULES, POLYPEPTIDES, ANTIBODIES, AND COMPOSITIONS SUITABLE THEREOF FOR THE TREATMENT AND DETECTION OF INFLUENZA AVIRUS INFECTION
BR0204479B1 (pt) processo para preparar misturas de reaÇço estabilizadas que sço total ou parcialmente secas, compreendendo pelo menos uma enzima, misturas de reaÇço e kits contendo as referidas misturas
EP1379693A4 (en) BIO STICK CODES BASED ON OLIGONUCLEOTIDE-MODIFIED PARTICLES
AU2002341621A1 (en) Methods, reagents, kits and apparatus for protein function analysis
WO2005003394A3 (en) Bio-barcode based detection of target analytes
WO2003072803A3 (en) Nanostructures containing antibody assembly units
WO2003062462A3 (en) Method for isolating nucleic acids and protein from a single sample
WO2004087875A3 (en) Nucleic acid-associated proteins
WO2005094467A3 (en) Methods for reducing the range in concentrations of analyte species in a sample
WO2008003489A8 (de) Zellulärer pyrogentest mittels toll-like rezeptor
WO2011142781A3 (en) Pore-limit electrophoresis (ple) microchannel assays
DE60024177D1 (de) Kugelförmige vernetzte organische Partikel, Suspensionen und Verfahren zur Herstellung von kugelförmigen vernetzten organischen Partikeln und Suspensionen
WO2020005846A8 (en) Labeling of dna
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
EP2295979A3 (en) Protein detection reagents and methods with dyes and dextrins
DE69738454D1 (de) Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
WO2004046314A3 (en) Methods for detecting asymmetric dimethylarginine in a biological sample
WO2003094848A3 (en) Nucleic acid-associated proteins
IL173843A0 (en) Assay for coronaviruses, reagents for use therein and kits containing the same
WO2006076687A3 (en) Elisa assays using prion-specific peptide reagents
DE69913325D1 (de) Nephrin gen und protein
WO2002026929A3 (en) Kini-3 motor protein and methods for its use
DE50112878D1 (de) Nachweis von pathogenen bakterien

Legal Events

Date Code Title Description
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2711 DE 20-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.